Zonisamide in the Treatment of Binge Eating Disorder With Obesity
Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267-0559, USA. The Journal of Clinical Psychiatry
(Impact Factor: 5.5).
12/2006; 67(12):1897-906. DOI: 10.4088/JCP.v67n1209
Binge eating disorder (BED) is associated with obesity. Zonisamide is a novel antiepileptic drug associated with weight loss. The purpose of this study was to evaluate zonisa-mide in the treatment of BED associated with obesity.
In this 16-week, single-center, randomized, double-blind, placebo-controlled, flexible-dose (100-600 mg/day) trial, 60 outpatients with DSM-IV-TR BED received zonisamide (N = 30) or placebo (N = 30). The primary outcome measure was weekly frequency of binge eating episodes. The primary analysis of efficacy was a longitudinal analysis of the intent-to-treat sample, with treatment-by-time interaction as the effect measure. Patients were enrolled from September 5, 2003, through October 1, 2004.
Compared with placebo, zonisamide was associated with a significantly greater rate of reduction in binge eating episode frequency (p = .021), body weight (p < .001), BMI (p = .001), and scores on the Clinical Global Impressions-Severity scale (p < .001), Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (p < .001), and Three Factor Eating Questionnaire disinhibition scales (p < .001). Plasma ghrelin concentrations increased with zonisamide but decreased with placebo (p = .001). The mean (SD) zonisamide daily dose at endpoint evaluation was 436 (159) mg/day. Twelve patients (N = 8 receiving zonisamide, N = 4 receiving placebo) discontinued because of adverse events. The most common reasons for discontinuing zonisamide were accidental injury with bone fracture (N = 2), psychological complaints (N = 2), and cognitive complaints (N = 2).
Zonisamide was efficacious, but not well tolerated, in the short-term treatment of BED associated with obesity.
ClinicalTrials.gov identifier NCT00221442.
Available from: Young-Hoon Ko
- "The broad pharmacodynamic properties of zonisamide suggest that they have potential effects on other neuropsychiatric disorders. Several clinical trials have investigated the effectiveness of zonisamide on migraines (Ashkenazi et al., 2006; Drake et al., 2004), chronic pain (Krusz, 2003), bipolar affective disorder (Berigan, 2002; Ghaemi et al., 2008; McElroy et al., 2005; Wang et al., 2008), binge eating disorder (McElroy et al., 2006), and obesity(Gadde et al., 2003; McElroy et al., 2006; Wang et al., 2008; Yang et al., 2010). "
[Show abstract] [Hide abstract]
ABSTRACT: This study examined the long-term effectiveness and tolerability of zonisamide for weight control in psychiatric outpatients using various psychotropic medications. We conducted a systematic chart review of 82 psychiatric outpatients with unwanted weight gain after the introduction of psychotropic drugs between January 2008 and September 2009 at Korea University Ansan Hospital. The primary outcome measure was the effect of zonisamide on body mass index (BMI). Additional outcome measures included safety and tolerability as assessed by the clinical global impression-severity of illness scale (CGI-S) and discontinuation rate. The mean final dose of zonisamide was 124.6±53.4 mg/day and ranged from 50mg/day to 300 mg/day. The mean BMI reduction was 0.8±1.7 kg/m(2) and ranged from -2.9 kg/m(2) to 4.7 kg/m(2) (p<0.001). We also observed a significant reduction in CGI-S scores from the baseline (3.8±0.9) to the endpoint (3.3±0.8; p<0.001). Twelve patients (14.6%) discontinued their zonisamide treatment due to its side effects. Patients treated with zonisamide showed significant weight loss. Furthermore, its treatment was generally safe and well tolerated with few negative effects on patients' overall psychiatric symptoms. Additional research is required to confirm these results and to investigate whether patients have rebound weight gains after discontinuing zonisamide.
Available from: Bruno Halpern
- "As seen in other studies of epileptic patients, there was a significant increase of serum creatinine of 0.13 mg/dL in the treated group compared to 0.03 mg/dL in the placebo group. In a subsequent study with obese patients with binge eating disorder (BED), zonisamide (in doses up to 600 mg/day) also proved effective both in reducing weight and in controlling bingeing episodes . "
[Show abstract] [Hide abstract]
ABSTRACT: Obesity is a chronic disease associated with excess morbidity and mortality. Clinical treatment, however, currently offers disappointing results, with very high rates of weight loss failure or weight regain cycles, and only two drugs (orlistat and sibutramine) approved for long-term use. Drugs combinations can be an option for its treatment but, although widely used in clinical practice, very few data are available in literature for its validation. Our review focuses on the rationale for their use, with advantages and disadvantages; on combinations often used, with or without studies; and on new perspectives of combinations being studied mainly by the pharmaceutical industry.
Available from: Oscar Arias-Carrion
- "After extensive studies it became available in 1989 for the treatment of intractable epilepsy in Japan and received over 10 years later approval in the USA and Europe for adjunctive treatment of partial seizures in adults (Murata, 2004). Besides treatment of epilepsy, there has been a growing interest in the therapeutic potential of zonisamide for treating non-seizure conditions, such as intractable neuropathic pain (Atli and Dogra, 2005), headache (Drake et al., 2004), obesity and binge eating disorder (McElroy et al., 2006) and Parkinson's disease (PD) (Murata et al., 2001). Particular in PD, studies reporting positive effects of zonisamide have become more frequent. "
[Show abstract] [Hide abstract]
ABSTRACT: Zonisamide is widely used as an antiepileptic drug. Two studies published recently in Experimental Neurology focus on the drug's neuroprotective effect. In the present commentary, we discuss the significance of their findings and aspects of zonisamide in neuroprotection.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.